Potential Dilution from the Exercise of Stock Acquisition Rights
First written in FY2018. 25 of 26 entries say "Materialised", first in FY2019-Q3. Latest entry: 2026-10-15.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- 2026-10-15MaterialisedEarnings
「新株予約権の行使による株式の発行による収入 11,700」
当中間期にも新株予約権の行使による株式発行が行われ、希薄化が継続している。 - FY2027-H1MaterialisedAnnual report
「1 March 2026–31 August 2026 195,000 63,268,990 5,850 5,947,760 5,850 65,963 (Note) The increase was due to the exercise of stock acquisition rights.」
The company issued an additional 195,000 shares upon the exercise of stock acquisition rights, and the dilution of equity value continued. - FY2026MaterialisedAnnual report
「Common shares 63,073,990 62,549,000 524,990 － (Note) Resulting from the issuance of new shares upon exercise of stock acquisition rights. / As of the filing date of this document, the number of potential shares from stock acquisition rights was 1,872,010, equivalent to 3.36% of total shares issued, excluding treasury shares.」
During the fiscal year, 524,990 shares were issued through the exercise of stock acquisition rights, and dilution continued. As of the filing date, potential shares totaled 1,872,010, equivalent to 3.36% of total shares issued. - 2026-05-01MaterialisedGeneral Meetings of Shareholders
「Common shares 62,549,000 shares 524,990 shares － shares 63,073,990 shares」
The company disclosed an increase of 524,990 in issued shares during the fiscal year through the exercise of stock acquisition rights and other transactions, indicating continued dilution of equity value. - FY2025MaterialisedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 2,397,000, equivalent to 3.97% of total shares issued, excluding treasury shares.」
During the fiscal year, 314,000 shares were issued through the exercise of stock acquisition rights, and dilution continued. As of the filing date, potential shares totaled 2,397,000, equivalent to 3.97% of total shares issued. - FY2025-Q1MaterialisedAnnual report
「Between 1 June 2024 and 30 June 2024, the exercise of share acquisition rights resulted in an increase of 19,000 in the total number of shares issued and increases of ¥2,692 thousand each in share capital and capital surplus.」
After the end of the quarter, an additional 19,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value has continued. - FY2024MaterialisedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 2,883,000, equivalent to 4.74% of total shares issued, excluding treasury shares.」
During the fiscal year, 240,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value continued. As of the filing date, potential shares totaled 2,883,000, equivalent to 4.74% of total shares issued. - FY2024-Q3MaterialisedAnnual report
「Between 1 December 2023 and 31 December 2023, the exercise of share acquisition rights resulted in increases of 195,000 in the total number of shares issued and ¥5,850 thousand each in share capital and capital surplus.」
After the end of the third quarter accounting period, an additional 195,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value has continued. - FY2024-Q1MaterialisedAnnual report
「1 March 2023–31 May 2023 45,000 62,040,000 6,376 5,908,768 6,376 26,971 (Note) Increase resulting from the exercise of share acquisition rights.」
An additional 45,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value has continued. - FY2023MaterialisedAnnual report
「Common shares 61,995,000 58,596,500 65,000 － (Note) Resulting from the issuance of new shares upon exercise of stock acquisition rights. / As of the filing date of this document, the number of potential shares from stock acquisition rights was 2,956,000, equivalent to 4.87% of total shares issued, excluding treasury shares.」
During the fiscal year, 65,000 shares were issued through the exercise of stock acquisition rights, and dilution continued. As of the filing date, potential shares totaled 2,956,000, equivalent to 4.87% of total shares issued. - FY2023-Q3MaterialisedAnnual report
「1 September 2022–30 November 2022 (Note) 50,000 61,980,000 1,500 5,901,941 1,500 20,145 (Note) The increase resulted from the exercise of stock acquisition rights.」
During the quarter, 50,000 shares were issued through the exercise of stock acquisition rights, and share capital and capital surplus each increased by ¥1.5 million. Dilution of shareholder value has continued. - FY2023-Q2MaterialisedAnnual report
「From 1 September 2022 to 30 September 2022, the exercise of stock acquisition rights increased total shares issued by 50,000 shares and increased share capital and capital surplus by ¥1.5 million each.」
After the end of the quarter, an additional 50,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value has continued. - FY2022MaterialisedAnnual report
「Common shares 61,930,000 58,596,500 3,333,500 －」
From 1 March 2021 to 28 February 2022, 3,333,500 shares were issued through the exercise of stock acquisition rights, and dilution continued. The filing states that, as of the filing date, potential shares totaled 3,188,000, equivalent to 5.23% of total shares issued. - FY2022-Q3MaterialisedAnnual report
「From 1 December 2021 to 31 December 2021, the exercise of stock acquisition rights increased total shares issued by 100,000 shares and increased share capital and capital surplus by ¥50,000 each.」
After the end of the quarter, an additional 100,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value has continued. - FY2022-Q2MaterialisedAnnual report
「1 June 2021–31 August 2021 49,500 61,830,000 1,485 5,900,391 1,485 18,595 (Note) Increase resulting from the exercise of share acquisition rights.」
During the quarter, 49,500 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value continues. - FY2022-Q1MaterialisedAnnual report
「1 March 2021–31 May 2021 3,184,000 61,780,500 9,970 5,898,906 9,970 17,110 (Note) Increase resulting from the exercise of share acquisition rights.」
During the quarter, 3,184,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value continued. - FY2021MaterialisedAnnual report
「During the fiscal year, 238,000 common shares were issued through the exercise of the Series 2 Stock Acquisition Rights. As of the filing date of this document, the number of potential shares from stock acquisition rights was 6,521,500, equivalent to 11.13% of the total number of shares issued.」
The issuance of 238,000 shares through the exercise of stock acquisition rights took place, and dilution continued. The disclosure also provides the number of potential shares and their percentage of total shares issued as of the filing date. - FY2021-Q3MaterialisedAnnual report
「1 September 2020–30 November 2020 43,000 58,596,500 1,290 5,888,936 1,290 7,140 (Note) Increase resulting from the exercise of share acquisition rights.」
During the quarter, 43,000 shares were issued through the exercise of stock acquisition rights, and dilution of shareholder value has continued. - FY2021-Q2MaterialisedAnnual report
「1 June 2020–31 August 2020 (Note 2) 195,000 58,553,500 5,850 5,887,646 5,850 5,850 (Note) 2. The increase resulted from the exercise of stock acquisition rights. 3. From 1 September 2020 to 30 September 2020, the exercise of stock acquisition rights increased total shares issued by 25,000 shares and increased share capital and capital surplus by ¥750,000 each.」
During the quarter, 195,000 shares were issued through the exercise of stock acquisition rights, and a further 25,000 shares were issued by the filing date. Dilution of shareholder value has continued. - FY2020MaterialisedAnnual report
「Number of bonds with stock acquisition rights with an exercise price adjustment clause, etc., exercised during the period (units): 3,000; number of shares delivered upon exercise during the period (shares): 3,000,000; funds raised through exercise during the period (¥ thousands): 7,407,492」
Through the exercise of the Series 5 Stock Acquisition Rights, 3,000,000 shares were delivered during the full year and ¥7,407.492 million was raised. Dilution has actually progressed. - FY2020-Q3MaterialisedAnnual report
「During the first 3 quarters of the fiscal year, share capital and capital surplus each increased by ¥3,726.226 million. This was mainly attributable to the issuance of new shares upon the exercise of the Series 5 Stock Acquisition Rights issued on 5 November 2018, which included an exercise price adjustment clause, an option to adjust the lower exercise price and an exercise authorization clause.」
The issuance of new shares upon exercise of the Series 5 Stock Acquisition Rights continued, resulting in further dilution of shareholder value. The share movement table disclosed an increase of 73,000 shares from 1 September to 30 November 2019. - FY2020-Q2MaterialisedAnnual report
「During the second quarter accounting period, the stock acquisition rights attached to bonds with stock acquisition rights with an exercise price adjustment clause, etc., were exercised as follows. Series 5 Stock Acquisition Rights: number of bonds with stock acquisition rights, etc., exercised during the quarter (units): 260; number of shares delivered upon exercise during the quarter (shares): 260,000; funds raised through exercise during the quarter (¥ thousands): 596,385; cumulative number of bonds with stock acquisition rights, etc., exercised as of the end of the quarter (units): 3,000; cumulative number of shares delivered under the bonds with stock acquisition rights, etc., as of the end of the quarter (shares): 3,000,000; cumulative funds raised under the bonds with stock acquisition rights, etc., as of the end of the quarter (¥ thousands): 7,407,492」
Through the exercise of the Series 5 Stock Acquisition Rights, 260,000 shares were delivered during the quarter and 3,000,000 shares cumulatively, resulting in further dilution of shareholder value. - FY2020-Q1MaterialisedAnnual report
「Number of convertible bonds with share acquisition rights and other instruments with an exercise price adjustment clause exercised during the quarter (units): 2,740; number of shares delivered upon exercise during the quarter (shares): 1,370,000; funds raised through exercises during the quarter (¥ thousand): 6,811,107」
Through the exercise of the Series 5 Stock Acquisition Rights, 1,370,000 shares were delivered, resulting in actual funding and dilution of shareholder value. - FY2019MaterialisedAnnual report
「Number of bonds with stock acquisition rights with an exercise price adjustment clause, etc., exercised during the fourth quarter (units): 1,510; number of shares delivered upon exercise during the period (shares): 755,000; funds raised through exercise during the period (¥ thousands): 2,433,327」
Through the exercise of the Series 4 Stock Acquisition Rights, a cumulative total of 1,000,000 shares were delivered for the full year, raising ¥3,182.603 million. Dilution has actually occurred. - FY2019-Q3MaterialisedAnnual report
「Number of bonds with stock acquisition rights with an exercise price adjustment clause, etc., exercised during the quarter (units): 490; number of shares delivered upon exercise during the quarter (shares): 49,000; funds raised through exercise during the quarter (¥ thousands): 749,276」
Through the exercise of the Series 4 Stock Acquisition Rights, 49,000 shares were delivered upon the exercise of 490 rights, raising ¥749.276 million. Dilution from the exercise of stock acquisition rights has actually occurred. - FY2018First statedAnnual report
「As of the filing date of this document, the number of potential shares from stock acquisition rights was 859,800, equivalent to 16.63% of the total number of shares issued.」
The disclosure quantifies the number of potential shares from stock options and other instruments and their percentage of total shares issued.